MingMed to Present at the 40th Annual J.P. Morgan Healthcare Conference

GUANGZHOU,China,Jan. 6,2022 -- MingMed Biotechnology,a clinical stage company dedicated to developing First-in-Class pharmaceutical products,today announced that Ms. Liza Ko,Chief Financial Officer of the company,has been invited to present at the 40th Annual J.P. Morgan Healthcare Conference on Monday,Jan. 10,2022 at 08:00 AM ET (09:00 PM,2022 Beijing Time),on the company and its latest R&D progress.

Registered participants of the J.P. Morgan Healthcare Conference may view the presentation online using the link below. The replay will be available for 30 days post the conference:

https://jpmorgan.metameetings.net/events/healthcare22/sessions/40605-mingmed-biotechnology-co-ltd/webcast?gpu_only=true&kiosk=true

About MingMed

MingMed Biotechnology is a clinical stage company dedicated to developing First-in-Class pharmaceutical products. Our team is formed by global top-notch scientists and specialists,while our scientific committee consists of influential scientists in the world. The company has already made world-class breakthroughs in developing novel therapies in the fields of ophthalmology,medical aesthetics,immuno-oncology and cell therapy. There are currently over 10 products in the R&D pipeline,most of which are First-in-Class medications for unmet medical needs and are at clinical stage.

For more information,please visit: www.ming-med.com

Media Contact: Jan Zhou

Email Address: ming-med@ming-med.com